Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Bruce J MacLachlan"'
Autor:
Yuan Chen, Georgina H. Mason, D. Oliver Scourfield, Alexander Greenshields-Watson, Tracey A. Haigh, Andrew K. Sewell, Heather M. Long, Awen M. Gallimore, Pierre Rizkallah, Bruce J. MacLachlan, Andrew Godkin
Publikováno v:
Cell Reports, Vol 42, Iss 8, Pp 112827- (2023)
Summary: CD4+ T cells recognize a broad range of peptide epitopes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which contribute to immune memory and limit COVID-19 disease. We demonstrate that the immunogenicity of SARS-CoV-2 pept
Externí odkaz:
https://doaj.org/article/89d593fdc3ac46c694db2226da7cae58
Autor:
Shoeib Moradi, Sanda Stankovic, Geraldine M. O’Connor, Phillip Pymm, Bruce J. MacLachlan, Camilla Faoro, Christelle Retière, Lucy C. Sullivan, Philippa M. Saunders, Jacqueline Widjaja, Shea Cox-Livingstone, Jamie Rossjohn, Andrew G. Brooks, Julian P. Vivian
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
KIR2DL2 and KIR2DL3 are two inhibitory members of the killer-cell immunoglobulin-like receptors (KIR) family that share a common HLA-I preference in binding HLA from the C1 group. However, it is still unclear to what extent binding and function is eq
Externí odkaz:
https://doaj.org/article/2e2f5009dd934a8381838529885caa65
Autor:
Rory M. Crean, Bruce J. MacLachlan, Florian Madura, Thomas Whalley, Pierre J. Rizkallah, Christopher J. Holland, Catriona McMurran, Stephen Harper, Andrew Godkin, Andrew K. Sewell, Christopher R. Pudney, Marc W. van der Kamp, David K. Cole
Publikováno v:
Molecular Therapy: Oncolytics, Vol 18, Iss , Pp 443-456 (2020)
Immuno-oncology approaches that utilize T cell receptors (TCRs) are becoming highly attractive because of their potential to target virtually all cellular proteins, including cancer-specific epitopes, via the recognition of peptide-human leukocyte an
Externí odkaz:
https://doaj.org/article/468343d29a914222a4306cde545a8b9d
Autor:
Alexander Greenshields-Watson, Meriem Attaf, Bruce J. MacLachlan, Thomas Whalley, Cristina Rius, Aaron Wall, Angharad Lloyd, Hywel Hughes, Kathryn E. Strange, Georgina H. Mason, Andrea J. Schauenburg, Sarah L. Hulin-Curtis, James Geary, Yuan Chen, Sarah N. Lauder, Kathryn Smart, Dhanasekaran Vijaykrishna, Miguel L. Grau, Mikhail Shugay, Robert Andrews, Garry Dolton, Pierre J. Rizkallah, Awen M. Gallimore, Andrew K. Sewell, Andrew J. Godkin, David K. Cole
Publikováno v:
Cell Reports, Vol 32, Iss 2, Pp 107885- (2020)
Summary: T cell recognition of peptides presented by human leukocyte antigens (HLAs) is mediated by the highly variable T cell receptor (TCR). Despite this built-in TCR variability, individuals can mount immune responses against viral epitopes by usi
Externí odkaz:
https://doaj.org/article/ac1881b0cc804226bb104e9cab830657
Autor:
Christopher J. Holland, Bruce J. MacLachlan, Valentina Bianchi, Sophie J. Hesketh, Richard Morgan, Owen Vickery, Anna M. Bulek, Anna Fuller, Andrew Godkin, Andrew K. Sewell, Pierre J. Rizkallah, Stephen Wells, David K. Cole
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
T-cell immunity is controlled by T cell receptor (TCR) binding to peptide major histocompatibility complexes (pMHCs). The nature of the interaction between these two proteins has been the subject of many investigations because of its central role in
Externí odkaz:
https://doaj.org/article/e3ef9d8a5f414323a84758bdf8c25ac1
Autor:
Julian P. Vivian, Gabrielle M. Watson, Dene R. Littler, Benjamin S. Gully, Bruce J. MacLachlan
Publikováno v:
Biochemical Society Transactions
The race to identify a successful treatment for COVID19 will be defined by fundamental research into the replication cycle of the SARS-CoV-2 virus. This has identified five distinct stages from which numerous vaccination and clinical trials have emer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::734e8f9fb34674656a0204f30346bde8
https://doi.org/10.1042/bst20200396
https://doi.org/10.1042/bst20200396
Autor:
Georgina H. Mason, David K. Cole, Frédéric Triebel, Awen Gallimore, Andrew James Godkin, Bruce J. MacLachlan, Alexander Greenshields-Watson
Publikováno v:
European Journal of Immunology
Immune checkpoint inhibitors (antibodies that block the T cell co‐inhibitory receptors PD‐1/PD‐L1 or CTLA‐4) have revolutionized the treatment of some forms of cancer. Importantly, combination approaches using drugs that target both pathways
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::295dfce87346771adca4707fe21a976b
https://doi.org/10.1002/eji.202048753
https://doi.org/10.1002/eji.202048753
Autor:
Yuanchen Deng, Andrew G. Brooks, Jamie Rossjohn, Philippa M. Saunders, Julian P. Vivian, Shu Cheng Wong, Bruce J. MacLachlan, Patricia T. Illing, Anthony W. Purcell, Phillip Pymm, Clare V. Oates
Publikováno v:
Proc Natl Acad Sci U S A
Micropolymorphisms within human leukocyte antigen (HLA) class I molecules can change the architecture of the peptide-binding cleft, leading to differences in peptide presentation and T cell recognition. The impact of such HLA variation on natural kil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67308cd5b11c4b74bddd19c641937ee0
https://doi.org/10.1073/pnas.1920570117
https://doi.org/10.1073/pnas.1920570117
Publikováno v:
Discovery Immunology. 1
The intracellular proteome of virtually every nucleated cell in the body is continuously presented at the cell surface via the human leukocyte antigen class I (HLA-I) antigen processing pathway. This pathway classically involves proteasomal degradati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9ce8bfd461c86af920b3b04e4cc1571
https://doi.org/10.1093/discim/kyac001
https://doi.org/10.1093/discim/kyac001
Autor:
Stephanie E A Burnell, Lorenzo Capitani, Bruce J MacLachlan, Georgina H Mason, Awen M Gallimore, Andrew Godkin
Publikováno v:
Immunotherapy advances. 2(1)
Despite three decades of research to its name and increasing interest in immunotherapies that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well-established PD-1 and CTLA-4. As such, LAG-3 targeting therapies have ye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::819e5445403ad7717dfa0b6d2dd0d01c
https://pubmed.ncbi.nlm.nih.gov/35265944
https://pubmed.ncbi.nlm.nih.gov/35265944